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ABSTRACT
Introduction The commensal intestinal microbiota drive
the inflammation associated with Crohn’s disease.
However, bacteria such as bifidobacteria and
Faecalibacterium prausnitzii appear to be
immunoregulatory. In healthy subjects the intestinal
microbiota are influenced by prebiotic carbohydrates
such as fructo-oligosaccharides (FOS). Preliminary data
suggest that FOS increase faecal bifidobacteria, induce
immunoregulatory dendritic cell (DC) responses and
reduce disease activity in patients with Crohn’s disease.
Aims and methods To assess the impact of FOS in
patients with active Crohn’s disease using an adequately
powered randomised double-blind placebo-controlled
trial with predefined clinical, microbiological and
immunological end points. Patients with active Crohn’s
disease were randomised to 15 g/day FOS or non-
prebiotic placebo for 4 weeks. The primary end point
was clinical response at week 4 (fall in Crohn’s Disease
Activity Index of $70 points) in the intention-to-treat
(ITT) population.
Results 103 patients were randomised to receive FOS
(n¼54) or placebo (n¼49). More patients receiving FOS
(14 (26%) vs 4 (8%); p¼0.018) withdrew before the
4-week end point. There was no significant difference in
the number of patients achieving a clinical response
between the FOS and placebo groups in the ITT analysis
(12 (22%) vs 19 (39%), p¼0.067). Patients receiving
FOS had reduced proportions of interleukin (IL)-6-positive
lamina propria DC and increased DC staining of IL-10
(p<0.05) but no change in IL-12p40 production. There
were no significant differences in the faecal
concentration of bifidobacteria and F prausnitzii between
the groups at baseline or after the 4-week intervention.
Conclusion An adequately powered placebo-controlled
trial of FOS showed no clinical benefit in patients with
active Crohn’s disease, despite impacting on DC
function. ISRCTN50422530.
INTRODUCTION
Crohn’s disease (CD) is a chronic inﬂammatory
condition of the gastrointestinal tract driven by
abnormal T cell responses to the intestinal micro-
biota. However, the commensal microbiota also
shape the development of the intestinal immune
system and protect against inﬂammation in animal
models.1e3 Speciﬁc bacterial species have distinct
immunological effects mediated by dendritic
cells (DC) which sample bacteria from the intes-
tinal lumen and direct the subsequent functional
differentiation of naive T cells into effector or
regulatory populations.4 5 Studies on human DC
have demonstrated immunoregulatory effects of
biﬁdobacteria, which increase DC interleukin
(IL)-10 production and decrease interferon-g release
from DC-activated allogeneic CD4+T cells.6 Like-
wise, the ﬁrmicute Faecalibacterium prausnitzii
reduces peripheral blood mononuclear cell IL-12 and
increases IL-10 release in vitro.7
In support of the differential effects of bacteria
on intestinal inﬂammation, marked differences in
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Significance of this study
What is already known about this subject?
< Active Crohn’s disease is associated with
alterations in intestinal microbiota (dysbiosis).
< Bifidobacteria and Faecalibacterium prausnitzii
enhance intestinal dendritic cell immunoregula-
tory responses and are reduced in active
disease.
< Fructo-oligosaccharides increase faecal bifido-
bacteria and F prausnitzii in healthy subjects.
< An open-label trial in patients with mildly active
Crohn’s disease found that fructo-oligosaccha-
rides increased faecal bifidobacteria, increased
intestinal dendritic cell interleukin 10 release and
reduced disease activity.
What are the new findings?
< Fructo-oligosaccharides do not enhance bifido-
bacteria and F prausnitzii in patients with active
Crohn’s disease.
< This treatment was shown to be ineffective at
inducing remission in an adequately powered
double-blind placebo-controlled trial.
< Fructo-oligosaccharides do impact on intestinal
dendritic cell function.
How might it impact on clinical practice in the
foreseeable future?
< Fructo-oligosaccharides are not an effective
treatment for active Crohn’s disease.
< Further studies of the microbiological, immuno-
logical and clinical effects of fructo-oligosac-
charides in maintaining disease remission are
required.
< A clinical benefit of an intervention that exerts
a prebiotic effect cannot be excluded.
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both faecal and mucosal microbiota (dysbiosis) in patients with
active CD compared with both inactive disease and healthy
subjects have been reported.3 Although results vary owing to
differences in both the patient groups studied and the microbi-
ological method used, higher concentrations of bacteroides and
Escherichia coli8 9 and lower concentrations of biﬁdobacteria10
and F prausnitzii7 11 have been reported in faecal and mucosal
samples from patients with CD compared with healthy
controls. Lower concentrations of F prausnitzii have been
found in patients with active disease than in those with quies-
cent disease, and low levels of this organism in CD resection
specimens predict subsequent endoscopic disease recurrence.7 11
The importance of the intestinal microbiota in the aetiology
of mucosal inﬂammation provides the rationale for therapeutic
strategies using probiotics and prebiotics in patients with CD.
Despite clear evidence of beneﬁt in animal models, well-designed
studies of probiotics have shown no beneﬁt in either the treat-
ment of active disease or the prevention of clinical and endo-
scopic recurrence after ileocaecal resection.12e15 Prebiotics are
non-digestible selectively fermented short-chain carbohydrates
that stimulate the growth and/or activity of a limited number of
the gut microbiota resulting in health beneﬁts to the host.16 For
example, oligofructose and inulin are polymers of fructose found
naturally in artichoke, asparagus and onions17 that increase
commensal faecal and mucosal biﬁdobacteria and F prausnitzii in
healthy humans.18 19 In addition, prebiotic fermentation results
in the production of short-chain fatty acids such as butyrate20
that enhance epithelial integrity and promote regulatory DC
function in vitro 21 In animal models of colitis, fructo-oligo-
saccharides (FOS) increased luminal biﬁdobacteria, inhibited
intracellular transcription factors such as NFkB and reduced
disease activity.22 A pilot open-label study investigating the
effect of 15 g/day FOS in mildly active CD reported a signiﬁcant
increase in faecal biﬁdobacteria, increased intestinal DC IL-10
release and a signiﬁcant reduction in disease activity as assessed
by the Harvey Bradshaw index.23
The aim of this study was to conduct the ﬁrst randomised
double-blind placebo-controlled trial with adequate power to
detect the clinical, immunological and microbiological impact of
FOS in a well-deﬁned population of patients with moderately
active CD.
MATERIALS AND METHODS
Trial design
This is a randomised double-blind placebo-controlled trial
conducted in line with CONSORT recommendations. Patients
were recruited from four inﬂammatory bowel disease outpatient
clinics in London. Based on the results of our previous open-label
study23 and assuming a response rate of 50% in the intervention
group and 20% in the placebo group, a total of 51 patients would
be required in each group to detect a difference between inter-
ventions with a signiﬁcance level of 0.05 and a power of 90%.
Patients
Adult patients with a documented diagnosis of CD for at least
3 months and a Crohn’s Disease Activity Index (CDAI) $220
with one additional marker of inﬂammation (elevated C reactive
protein (CRP)/erythrocyte sedimentation rate/platelet count)
were included. Exclusion criteria included the use of anti-tumour
necrosis factor agents in the preceding 12 weeks; antibiotics,
probiotics or prebiotics in the preceding 4 weeks; rectal prepa-
rations during the preceding 2 weeks; and any non-steroidal
anti-inﬂammatory drugs during the preceding week. Further
exclusion criteria included a change in dose of immunosup-
pressant within 12 weeks and oral 5-aminosalicylic acid or
steroids within 4 weeks. The maximum permissible steroid dose
was 20 mg/day. Other exclusion criteria included short bowel
syndrome, previous pan-proctocolectomy/signiﬁcant colonic
resection, sepsis, pure perianal disease and positive stool culture
for an enteropathogen.
Trial protocol
Informed consent was obtained prior to any study-related
procedures. During the 1-week screening patients completed
a diary to calculate disease activity (CDAI) and gave baseline
bloods with genotyping of common CARD 15 mutations.
Eligible patients were recruited and a fresh faecal sample was
collected for molecular microbiology and faecal calprotectin
analysis. Rectal biopsies were taken from normal rectal mucosa
at an unprepared ﬂexible sigmoidoscopy for DC immunological
analysis from a subset of patients recruited at St Mark’s
Hospital. Patients completed the Inﬂammatory Bowel Disease
Questionnaire (IBDQ, McMaster University, Canada). They
were given a symptom diary to monitor disease activity and side
effects.
A random number sequence was generated independently to
designate treatment assignment. Patients were randomised 1:1
to each group stratiﬁed by disease localisation (pure colonic
disease vs ileal involvement) and hospital site. Sachets of FOS
and placebo were packed in identical sequentially numbered
envelopes according to this code at each site. Both patients and
researcher were blinded to treatment assignation. Patients
randomised to the intervention group supplemented their
normal diet with 15 g/day FOS (Synergy1, Beneo-Orafti,
Belgium) which is classiﬁed as a food supplement by the UK
Medicines and Healthcare Products Regulatory Agency. This
comprised fructose polymers of differing chain lengths (70%
oligofructose with a degree of polymerisation (DP) <10 and 30%
inulin with a DP >10). Lower DP oligofructose is more rapidly
fermented in the proximal colon than higher DP inulin. Patients
in the placebo group received 15 g/day of a non-prebiotic
carbohydrate (maltodextrin). Both FOS and maltodextrin were
provided as identical 7.5 g sachets and patients were advised to
consume two sachets per day mixed with food or a cold beverage
for 4 weeks. Unused sachets were collected at the end of the
study period to calculate adherence. All patients remained on an
unrestricted diet and stable maintenance therapy for their CD
throughout the trial.
After the 4-week intervention period, patients were assessed by
the same investigator who remained blinded to treatment allo-
cation. The baseline investigations were repeated. Symptom
diaries were interrogated and rated on a scale of 0 (absent), 1
(mild), 2 (moderate), 3 (severe) and a sum of the daily scores was
calculated.24 Patients experiencing a signiﬁcant adverse event or
deterioration in disease activity requiring medical intervention
were withdrawn from the trial and treatedwith standard therapy
for CD. All randomised patients were included in the intention-
to-treat (ITT) population and the 4-week safety analysis.
Clinical end points
The primary end point was deﬁned as the percentage of patients
achieving a clinical response (fall in CDAI of $70 points) in the
ITT population at week 4. Predeﬁned secondary end points
included the percentage of patients achieving disease remission
(CDAI #150 points) at week 4, clinical response and remission
in the per protocol group, as well as a change in CDAI, CRP,
faecal calprotectin and quality of life (IBDQ) at week 4. There
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were no changes to the protocol or trial end points after
recruitment commenced.
Cytokine production by intestinal DCs
Ongoing DC cytokine production in the absence of exogenous
stimulation was assessed by intracellular staining and multi-
colour ﬂow cytometry of antibody-labelled dissociated lamina
propria mononuclear cells (LPMC) harvested from rectal biopsies
as previously described (full methodology given in online
supplement).25 For intracellular cytokine staining, paired cultures
of LPMCwith and without monensin were compared. Cells were
surface-labelled with anti-HLA-DR (BD Bioscience, Oxford, UK),
anti-CD11c (Dako, Ely, UK) and DC exclusion cocktail (lin; AbD
Serotec, Oxford, UK), then ﬁxed and permeabilised with leuco-
perm A and B. Anti-cytokine antibody (anti-IL-10-PE (AbD
Serotec), anti-IL-12p40-PE (BD Pharmingen, New Jersey, USA
and R&D Systems, Minneapolis, USA) and anti-IL-6-PE (R&D
Systems) were added. Data were acquired using a FACSCalibur
ﬂow cytometer (Beckton Dickinson, Oxford, UK). Using multi-
colour analysis, DC were identiﬁed as an HLA-DR+
lineage (CD3, CD14, CD16, CD19, CD34) population,
and within this gate, the CD11c+ (conventional DC) population
was assessed. The proportion of cytokine-positive cells was
determined by SED normalised subtraction using WinList soft-
ware (Verity Software House). The proportion of cytokine-
producing cells and the level of staining (intensity ratio) in
cytokine-positive cells were determined.
Faecal bifidobacteria and Faecalibacterium prausnitzii
Faecal biﬁdobacteria and F prausnitzii were quantiﬁed in fresh
faecal samples using ﬂuorescent in situ hybridisation as previ-
ously described (full methodology given in online supplement).23
Total cell counts were quantiﬁed using the nucleic acid stain
4,6-diamidino-2-phenlindole. Cells were hybridised with
Cy3-labelled oligonucleotide probes targeting regions of 16S
rRNA speciﬁc for biﬁdobacteria (59-GCT GCC TCC CGT AGG
AGT-39)26 and F prausnitzii (59-CCT CTG CAC TAC TCA AGA
AAA AC-39)27 (Microsynth, Balgach, Switzerland). The hybri-
dised bacteria were quantiﬁed manually by ﬂuorescence
microscopy and concentrations expressed as cells/g dry faeces.
Faecal calprotectin
The CALPRO Calprotectin ELISA test kit (Nova Tec, Dietzen-
bach, Germany) was used according to the manufacturer ’s
instructions.
Statistical analysis
Statistical analyses were performed using SPSS software package
V.16 (SPSS Software). Data were tested for normality using the
KolmogroveSmirnov and ShapiroeWilk tests. The results are
shown as mean (SD). The clinical outcome variables were
assessed by ITT and per protocol analyses. Comparison of
categorical data between patients in the FOS and placebo groups
was performed using the c2 method. If any cell in these analyses
had an expected count of <5, the Fisher exact test was used.
Comparison of continuous data between FOS and placebo was
performed using the Student t test. Comparison of continuous
data within groups was performed using paired t tests. The
results for all tests were considered signiﬁcant if p<0.05.
RESULTS
Patient cohort
Recruitment took place between September 2006 and April 2009
when complete accrual was achieved. The ﬁnal trial visit was in
May 2009. Of 217 patients screened, 95 did not meet the
inclusion criteria (56 had normal inﬂammatory markers, 33 had
a CDAI <220, 1 had a CDAI >450, 3 changed medication, 1 had
a positive stool culture and 1 was diagnosed with hepatitis C)
and 19 declined to participate. A total of 103 subjects were
therefore randomised (54 to FOS, 49 to placebo) and comprise
the ITT population (consort diagram available in online
supplement). Mean (SD) disease duration was 11 (7.7) years in
the FOS group and 10 (7.6) years in the placebo group (p¼0.48);
there were no signiﬁcant demographic differences between
groups (table 1). A single mutation in the CARD 15 gene was
present in 16 (16.3%) patients with one patient having
a compound heterozygote genotype (R702W and G908R), with
no difference in prevalence between groups.
Clinical outcomes
In the ITT population there was no signiﬁcant difference in the
number of patients achieving the primary end point of clinical
response at week 4 between patients in the FOS group (n¼12,
22%) and the placebo group (n¼19, 39%; p¼0.067). Likewise,
there was no signiﬁcant difference in the numbers achieving
clinical remission between groups (FOS n¼6, 11% vs placebo
n¼10, 20%, p¼0.193). The lack of difference in response and
remission rates remained when analysed per protocol (table 2).
At week 4 there was no signiﬁcant difference in the mean CDAI
between the FOS and placebo groups (mean (SD) 250 (84.9) vs
220 (88.7); p¼0.112). Predeﬁned subgroup analysis revealed no
beneﬁt of FOS in patients with isolated colonic disease or ileal
involvement. There were no signiﬁcant differences in IBDQ
scores between groups (per protocol) at baseline (FOS 120.3
(30.0) vs placebo 129.8 (26.5); p¼0.122), whereas at week 4 the
FOS group had a signiﬁcantly lower IBDQ score than the
placebo group (129.9 (36.3) vs 149.8 (24.5); p¼0.004).
In the per protocol group there were no differences in the
mean (SD) CRP level between the FOS and placebo groups at
baseline (18.8 (21.6) mg/l vs 20.8 (23.1) mg/l; p¼0.692) or at
4 weeks (20.9 (26.4) mg/l vs 20.2 (24.1) mg/l; p¼0.902). Faecal
calprotectin concentrations were available at baseline and at
4 weeks in 60 patients (28 FOS, 32 placebo). There were no
signiﬁcant differences in the mean (SD) values between groups
at either baseline (FOS 621.4 (559.4) mg/kg vs placebo 647.9
(533.3) mg/kg; p¼0.852) or week 4 (FOS 657.4 (592.5) mg/kg vs
Table 1 Characteristics of patients in the fructo-oligosaccharide (FOS)
and placebo groups
FOS (n[54) Placebo (n[49) p Value
Male, n (%) 18 (33%) 22 (45%) 0.229
Mean (SD) age, years 40 (14.8) 39 (13.7) 0.633
Mean (SD) duration of CD, years 11 (7.7) 10 (7.6) 0.477
Disease site, n (IC/colonic/SB) 39/10/5 33/12/4 0.759
Resection, n (%) 24 (44%) 14 (29%) 0.111
Smoker, n (%) 18 (33%) 11 (22%) 0.220
Mean (SD) CDAI at randomisation 283 (61) 286 (62) 0.794
Mean (SD) IBDQ at randomisation 121 (31) 129 (27) 0.169
Medication
Immunosuppression, n (%) 24 (44%) 26 (53%) 0.382
Azathioprine, n (%) 19 (35%) 20 (41%) 0.556
Methotrexate, n (%) 4 (7%) 6 (12%) 0.408
5-Aminosalicylates, n (%) 22 (41%) 25 (51%) 0.296
Prednisolone, n (%) 3 (6%) 3 (6%) 0.902
p Values calculated by the Student t test for continuous data and c2 test or Fisher exact test
for categorical data.
CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; IBDQ, Inflammatory Bowel
Disease Questionnaire; IC, ileocolonic; SB, small bowel.
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placebo 829.8 (635.9) mg/kg, p¼0.322). However, there was
a smaller increase in faecal calprotectin during the trial in the
FOS group (mean (SD) +61.5 (300.6) mg/kg) compared with the
placebo group (mean (SD) +296 (493.6) mg/kg; p¼0.092).
Adherence, gastrointestinal tolerance and adverse events
All patients who completed the intervention showed good
adherence with a mean (SD) intake of 89 (18.7)% of sachets in
the FOS group and 92 (11.8)% of sachets in the placebo group
(p¼0.355). The intake in those who completed the study was
13.3 (2.8) g/day in the FOS group compared with 13.8 (1.8) g/
day in the placebo group (p¼0.355).
At baseline there were no differences in the incidence or
severity of gastrointestinal symptoms between groups. During
week 4 there was a higher incidence of borborygmi in the FOS
group (4.7 (2.5) days/week) than in the placebo group (4.0
(2.6) days/week, p¼0.013). However, no differences were seen in
the incidence of any other symptoms. Throughout the trial,
patients in the FOS group had a signiﬁcantly greater severity of
ﬂatulence (p¼0.004), borborygmi (p¼0.029) and abdominal pain
(p¼0.048) than those in the placebo group (table 3).
Signiﬁcantly more patients in the FOS group than in the
placebo group withdrew before the end of the trial (n¼14, 26%
vs n¼4, 8%; p¼0.0018). Of those who withdrew, 10 patients
(19%) in the FOS group did so because of worsening symptoms
compared with 3 (6%) in the placebo group (p¼0.059). Baseline
calprotectin levels (when available) were signiﬁcantly higher in
those patients receiving FOS who subsequently withdrew due to
worsening symptoms (n¼5; 1068.5 (594.9) mg/kg) than in those
who completed the trial (n¼23; 524.1 (514.2) mg/kg; p¼0.046).
There were no differences in other baseline characteristics
between patients who withdrew and those who did not (data
not shown). Serious adverse events were reported in four
patients receiving FOS (three related to disease deterioration,
one admitted for an acute asthma attack) and two patients
receiving placebo (one disease deterioration and one car acci-
dent). No other adverse events were recorded.
Immunological analysis
Mucosal biopsies from histologically non-inﬂamed rectum at
both time points were available from 26 patients (13 patients
randomised to each group). In keeping with our previous
publication,23 there was a signiﬁcant increase in DC IL-10
staining between baseline and week 4 in patients in the FOS
group (median (IQR) intensity ratio increased from 1.3 (0.6) to
2.0 (1.6); p¼0.035), whereas no difference was seen in patients
receiving placebo (intensity ratio at baseline and week 4 was 1.4
(1.4) and 1.6 (1.0); p¼0.655, ﬁgure 1). There were no signiﬁcant
differences in IL-12p40 production by intestinal DC (percentage
positive or intensity ratio) between groups at baseline or week 4
(not shown). IL-6 production by DC is a key factor in over-
coming the inhibitory activity of T regulatory cells and enabling
the development of effector responses.28 There was a signiﬁcant
reduction in the mean (SD) proportion of IL-6-positive DC
during the intervention in patients receiving FOS (from 29 (12)
to 32 (15); p¼0.036) compared with placebo (from 32 (18) to
28 (15); p¼0.464, ﬁgure 2).
Microbiological analysis
There were no signiﬁcant differences in faecal concentrations of
biﬁdobacteria or F prausnitzii between the groups at baseline. In
contrast to studies of healthy volunteers, there was no signiﬁ-
cant difference in faecal concentrations of biﬁdobacteria at week
Table 2 Response and remission rates in the fructo-oligosaccharide
(FOS) and placebo groups
FOS Placebo p Value
Response*
Intention to treat, n (%) 12 (22%) 19 (39%) 0.067
Per protocol, n (%) 12 (30%) 19 (42%) 0.243
Remissiony
Intention to treat, n (%) 6 (11%) 10 (20%) 0.193
Per protocol, n (%) 6 (15%) 10 (22%) 0.395
Results of c2 tests.
*Response: primary end point (reduction in Crohn’s Disease Activity Index (CDAI) $70
points).
yRemission: CDAI #150.
Table 3 Comparison of severity of symptoms between fructo-
oligosaccharide (FOS) and placebo groups at baseline and during the
4-week trial period
Severity Baseline* p Value Trial scorey p Value
Acid reflux
FOS 2.5 (3.6) 4.0 (2.8)
Placebo 3.0 (3.9) 0.487 2.8 (3.5) 0.218
Rumbling gut
FOS 7.7 (4.9) 8.3 (4.0)
Placebo 7.8 (5.3) 0.900 6.0 (6.9) 0.029
Abdominal bloating
FOS 8.8 (5.5) 9.6 (5.5)
Placebo 7.7 (5.7) 0.321 7.4 (4.6) 0.061
Abdominal pain
FOS 11.2 (4.8) 10.2 (5.2)
Placebo 10.8 (4.3) 0.667 8.0 (2.7) 0.048
Flatulence
FOS 8.3 (5.0) 10.8 (5.2)
Placebo 8.0 (5.5) 0.780 8.0 (4.7) 0.004
*Mean (SD) cumulative score over a 7-day period using the following scoring system:
0¼absent; 1¼mild; 2¼moderate; 3¼severe.
yMean cumulative average score for the 4-week trial period.
Figure 1 Lamina propria mononuclear cells were dissociated from
mucosal biopsies taken from non-inflamed rectum at baseline and week
4 (n¼13 per group). Dendritic cells (DC) were identified as an HLA-DR+
lineage-(CD3, CD14, CD16, CD19, CD34) population and,
within this gate, the CD11c+ population was assessed. The intensity of
interleukin 10 (IL-10) expression was determined after intracellular
cytokine staining using SED normalised subtraction. Staining of cells
cultured in the absence of monensin was subtracted from staining of
cells cultured in the presence of monensin, giving a measure of ongoing
cytokine production. The median (IQR) intensity of CD11c+ DC IL-10
staining at baseline and week 4 is shown. FOS, fructo-oligosaccharide.
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4 between patients in the FOS and placebo groups (9.4 (0.6)
log10 cells/g dry faeces vs 9.3 (0.8) log10 cells/g dry faeces;
p¼0.201). In addition, there was no signiﬁcant difference in
faecal concentrations of F prausnitzii between patients in the
FOS and placebo groups at week 4 (8.7 (0.9) log10 cells/g dry
faeces vs 8.7 (1.0) log10 cells/g dry faeces; p¼0.95).
In order to investigate the absence of a prebiotic-induced
biﬁdogenesis in patients receiving FOS, the baseline character-
istics of patients who did experience a rise in biﬁdobacteria were
compared with those who did not. Patients receiving FOS who
experienced a large increase (>+0.5 log10 cells/g) in biﬁdobac-
teria (n¼7) had a lower CDAI at baseline than patients with no
increase in biﬁdobacteria ((n¼32) 248.1 (30.0) vs 290.0 (56.8);
p¼0.064). Likewise, they had lower faecal calprotectin concen-
trations (324.0 (468.1) mg/kg vs 683.2 (545.5) mg/kg; p¼0.130).
Previous ileocolic resection did not correlate with change in
biﬁdobacteria. Finally, as previously reported,29 an inverse
correlation was found between the baseline concentration of
biﬁdobacteria and the change in concentration of biﬁdobacteria
following FOS (ﬁgure 3).
There was no signiﬁcant difference in the CDAI change
between baseline and 4 weeks in patients receiving FOS who did
experience biﬁdogenesis compared with those that did not (29
(88.2) vs 35 (79.6); p¼0.855). There was also no signiﬁcant
difference in CRP between those with a biﬁdogenic effect and
those without, either at baseline (24.8 (23.8) vs 16.4 (21.2),
p¼0.311) or at 4 weeks (25.5 (27.0) vs 18.6 (25.7), p¼0.508).
DISCUSSION
We report the ﬁrst randomised double-blind placebo-controlled
trial of prebiotics in patients with active CD. The trial was
adequately powered to detect a clinically relevant difference in
response rates between patient groups and achieved complete
recruitment. The power calculation was based upon results from
our pilot open-label study and the placebo rate from a published
meta-analysis.30 In order to ensure participants had symptoms
related to active inﬂammation and to minimise placebo response
rates, inclusion required a CDAI consistent with moderately
active disease as well as another marker of active inﬂammation.
We found no signiﬁcant difference in the number of patients
meeting the primary end point (fall in CDAI of $70 points)
between the FOS and placebo groups. Likewise, there was no
difference between groups in the number of patients achieving
clinical remission (CDAI #150) or any other clinical secondary
end point.
FOS was associated with a signiﬁcantly increased incidence
and severity of gastrointestinal symptoms and more patients
randomised to this group withdrew from the trial than from the
placebo group. Gastrointestinal symptoms relating to FOS in
patients with inﬂammatory bowel disease probably result from
both an osmotic effect and bacterial fermentation.31 32 However,
this is unlikely to have masked a true therapeutic beneﬁt as per
protocol analyses also showed no difference in either response or
remission rates between groups. It is theoretically possible that
the increase in gastrointestinal symptoms associated with FOS
had a negative impact on subjective aspects of the CDAI,
therefore masking a true clinical beneﬁt. However, there were no
signiﬁcant improvements in objective markers of intestinal
inﬂammation such as CRP and faecal calprotectin in patients
receiving FOS compared with placebo. Finally, in view of
previous reports of increased efﬁcacy of dietary interventions in
CD patients with ileal involvement as opposed to pure colonic
disease, we stratiﬁed randomisation according to disease site.
However, our prespeciﬁed subgroup analysis did not demon-
strate a signiﬁcant beneﬁt of FOS compared with placebo in
either patients with ileal involvement or those with disease
limited to the colon, although the trial may be underpowered to
detect a difference in this subgroup analysis. We therefore
conclude that FOS is not an effective treatment for patients
with moderately active CD.
Patients with CD often enquire about alternative non-phar-
macological treatments for their disease. Indeed, we have
recently reported a high prevalence of their use among patients
with inﬂammatory bowel disease despite a lack of robust
evidence demonstrating clinical beneﬁt.33 There is therefore
a clear need for randomised placebo-controlled trials to deter-
mine the efﬁcacy of treatments that have shown promising
results in open-label trials. Factors that have been reported to be
associated with a high placebo response in CD trials include the
number of study visits, increased study duration, low baseline
Figure 2 Lamina propria mononuclear cells were dissociated from
mucosal biopsies taken from non-inflamed rectum at baseline and week
4 (n¼13 per group). Dendritic cells (DC) were identified as an HLA-DR+
lineage-(CD3, CD14, CD16, CD19, CD34) population and,
within this gate, the CD11c+ population was assessed. The
proportion of interleukin 6 (IL-6)-positive cells was determined after
intracellular cytokine staining using SED normalised subtraction. Staining
of cells cultured in the absence of monensin was subtracted from
staining of cells cultured in the presence of monensin, giving a measure
of ongoing cytokine production. The percentage of IL-6-positive
CD11c+ DC for each patient at baseline and week 4 is shown.
FOS, fructo-oligosaccharide.
Figure 3 Correlation between baseline concentrations of faecal
bifidobacteria (log10 cells/g dry faeces) and their change in concentration
after 15 g/day fructo-oligosaccharide (FOS) for 4 weeks in patients
randomised to the FOS group in whom stool samples were available at
both time points (n¼40; r¼0.618, p<0.001).
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CDAI and a normal CRP.30 Despite designing the protocol to
minimise the placebo rate, there was a high clinical response rate
in patients receiving placebo. Future studies of nutritional
interventions in this patient group will need to modify the
power calculation to take account of this.
Prebiotic carbohydrates such as FOS are selectively fermented
in the colon resulting in beneﬁcial alterations in the commensal
microbiota and short-chain fatty acid production.18e20 A
number of studies in healthy volunteers have shown that the
ingestion of at least 10 g/day results in a marked increase in
faecal and mucosal biﬁdobacteria and faecal F prausnitzii.18e20 In
the context of mildly active CD, our previous open-label trial
showed that 15 g/day FOS resulted in a signiﬁcant increase in
faecal biﬁdobacteria.23 Surprisingly, in this placebo-controlled
trial patients given 15 g/day FOS did not experience signiﬁcant
changes in faecal biﬁdobacteria. The documented adherence of
13.3 (2.8) g/day was sufﬁcient to induce biﬁdogenesis.34 Analysis
of the demographic features of the patients receiving FOS who
experienced the greatest biﬁdogenesis showed that disease
duration, previous ileocaecal resection and medication did not
impact on the microbiological response to FOS. However, there
was a signiﬁcant negative correlation between baseline biﬁdo-
bacteria concentration and subsequent increase after FOS (an
observation previously observed in healthy subjects29), which
suggests that patients with CD who have the lowest baseline
levels had the greatest potential for biﬁdogenesis. Interestingly,
the baseline biﬁdobacteria concentrations in patients randomised
to the FOS group in the current trial were signiﬁcantly higher
than those reported in our previous open-label trial where biﬁ-
dogenesis did occur (9.5 (0.5) vs 8.8 (0.9) log10 cell/g; p¼0.024).
Patients recruited to this open-label trial had less severe disease at
study entry than those recruited to the current trial.23 In keeping
with this, patients experiencing an increase in biﬁdobacteria in
our current trial had less active disease with lower baseline CDAI
score and faecal calprotectin levels. We therefore suggest that
prebiotic carbohydrates may have less impact on the intestinal
microbiota in patients with signiﬁcant intestinal inﬂammation,
although there was no signiﬁcant difference in the clinical
response of patients receiving FOS who did experience an
increase in biﬁdobacteria compared with those who did not.
Recent evidence suggests that modulation of DC function
contributes to the proinﬂammatory and immunoregulatory
effects of the intestinal microbiota on the mucosal immune
system.35 Thus, successful treatment with the probiotic VSL#3
in patients with ulcerative colitis is associated with a reduction
in DC IL-12p40 and an increase in DC IL-10.36 In our previous
open-label study in patients with mildly active CD, 15 g/day
FOS increased the percentage of intestinal DC expressing IL-10.23
We hypothesised that this effect was dependent on the biﬁdo-
genic effect of FOS acting via Toll-like receptors or other pattern
recognition receptors. However, despite no effect on the faecal
microbiota in the current trial, FOS still resulted in signiﬁcant
alterations in cytokine production by intestinal DC compared
with placebo, with an increase in IL-10 staining and a reduction
in IL-6 production. These data indicate that the changes in DC
cytokine expression are unlikely to result from alterations in
intestinal biﬁdobacteria. Alternative explanations include short-
chain fatty acid production following colonic fermentation of
the prebiotic as FOS has been reported to increase faecal butyrate
production in an in vitro fermentation system.37 Butyrate
inﬂuences DC maturation and cytokine production in vitro,
altering the balance of IL-12 and IL-10 production in favour of
the latter.21 In our current study, increased production of IL-10
and reduced IL-6 by DC indicated that DC cytokine production
was skewed by FOS towards a less inﬂammatory proﬁle, but this
was evidently not sufﬁcient to impact upon clinical disease.
Strikingly, unlike VSL#3, FOS did not alter DC IL-12p40 release,
which suggests that alterations in IL-12 or IL-23 production may
be more clinically relevant. It remains to be tested whether the
effects on DC may be signiﬁcant in the context of maintenance
of remission or disease prevention.
In conclusion, an adequately powered trial of FOS in a well-
deﬁned population of patients with active CD showed no clin-
ical beneﬁt despite impacting on DC immunology. A higher
severity of gastrointestinal symptoms was seen in patients
receiving FOS, and patient withdrawal was greater in this group.
This may add support to the concept that fermentable carbo-
hydrates may worsen functional symptoms associated with
CD.38 In contrast to previous studies in healthy subjects and
patients with mild CD, no signiﬁcant alteration in faecal
microbiota was seen in this cohort of patients with moderately
active CD. Our ﬁndings suggest that future research regarding
prebiotics in inﬂammatory bowel disease should focus on their
role in maintaining disease remission or perhaps preventing its
onset in those with a high-risk phenotype.
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